Revista Portuguesa de Cardiologia

2020

DOI: 10.1016/j.repc.2020.05.010

|View full text |Cite

|

Sign up to set email alerts

|

Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease

Ingrid Alves de Freitas

¹

,

Neiberg de Alcantara Lima

²

,

Geraldo Bezerra da Silva

³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction4

Epidemiology Of Cardiovascular Diseases In Chronic Kidney Di...1

Citation Types

Supporting

1

Mentioning

12

Contrasting

0

Unclassified

4

Year Published

2021

2021

2024

2024

Publication Types

Select...

Article9

Book1

Relationship

Self Cite0

Independent10

Authors

Journals

Cited by 23 publications

(17 citation statements)

References 19 publications

Supporting

1

Mentioning

12

Contrasting

0

Unclassified

4

Order By: Relevance

“…The main evidence suggested that elevated NGAL level is associated with better prognosis after cardiac arrest and with comorbid kidney injury. 62 Beside this, some recent data showed that NGAL may be a novel biomarker to aid in risk stratification in coronary heart disease patients. 63 It should be pointed out that monitoring of these markers could have significant importance for early diagnosis and clinical course, not only in patients with various forms of renal diseases but also in patients with cardiorenal syndrome, heart failure, cardiopulmonary bypass, and cardiothoracic surgery.…”

Section: Epidemiology Of Cardiovascular Diseases In Chronic Kidney Di...mentioning

confidence: 99%

Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease

¹

,

²

,

³

et al. 2022

Dose-Response

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is an important factor that contributes to the increase of all-cause morbidity and mortality in the group of non-communicable diseases, and it is also recognized as a strong and independent risk factor that contributes to cardiovascular disease (CVD). CVDs are a consequence of the action of a large number of risk factors among which are traditional and non-traditional. These risk factors have been the subject of a large number of studies which partially explained the unfavorable cardiovascular (CV) outcome of CKD patients. Therefore, valid studies about clinical and biohumoral predictors are of particular importance, especially in the early stages of renal disease, that is, in patients with creatinine clearance below 60 ml/min/1.73 m2 when preventive measures are most effective. Among potential predictors of adverse CV outcome are biomarkers of inflammation (Interleukin-18—IL-18), oxidative stress (ischemia-modified albumin—IMA; superoxide dismutase—SOD), acute kidney injury (kidney injury molecule -1—KIM-1; neutrophil gelatinase–associated lipocalin—NGAL), and microribonucleic acids (specific microRNA-133a). In this review, we tried to confirm the relationship between risk factors of CKD and CVD and newer, less frequently examined biomarkers with the occurrence of incidental CV events in renal patients.

“…The main evidence suggested that elevated NGAL level is associated with better prognosis after cardiac arrest and with comorbid kidney injury. 62 Beside this, some recent data showed that NGAL may be a novel biomarker to aid in risk stratification in coronary heart disease patients. 63 It should be pointed out that monitoring of these markers could have significant importance for early diagnosis and clinical course, not only in patients with various forms of renal diseases but also in patients with cardiorenal syndrome, heart failure, cardiopulmonary bypass, and cardiothoracic surgery.…”

Section: Epidemiology Of Cardiovascular Diseases In Chronic Kidney Di...mentioning

confidence: 99%

Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease

¹

,

²

,

³

et al. 2022

Dose-Response

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is an important factor that contributes to the increase of all-cause morbidity and mortality in the group of non-communicable diseases, and it is also recognized as a strong and independent risk factor that contributes to cardiovascular disease (CVD). CVDs are a consequence of the action of a large number of risk factors among which are traditional and non-traditional. These risk factors have been the subject of a large number of studies which partially explained the unfavorable cardiovascular (CV) outcome of CKD patients. Therefore, valid studies about clinical and biohumoral predictors are of particular importance, especially in the early stages of renal disease, that is, in patients with creatinine clearance below 60 ml/min/1.73 m2 when preventive measures are most effective. Among potential predictors of adverse CV outcome are biomarkers of inflammation (Interleukin-18—IL-18), oxidative stress (ischemia-modified albumin—IMA; superoxide dismutase—SOD), acute kidney injury (kidney injury molecule -1—KIM-1; neutrophil gelatinase–associated lipocalin—NGAL), and microribonucleic acids (specific microRNA-133a). In this review, we tried to confirm the relationship between risk factors of CKD and CVD and newer, less frequently examined biomarkers with the occurrence of incidental CV events in renal patients.

“…Acute myocardial infarction (AMI) is the major cause of CVD death [ 2 ], and its recommended management is focusing on the improvement of prognosis [ 3 ]. Utilizing biomarkers in clinical practice could guide prognostic stratification of individuals with AMI [ 4 ]. A perfect biomarker might help delve into the pathophysiology of, find new targets for treatment of, and develop primary and secondary prevention measures of CVDs.…”

Section: Introductionmentioning

confidence: 99%

Effect of Serum Spermidine on the Prognosis in Patients with Acute Myocardial Infarction: A Cohort Study

¹

,

²

,

³

et al. 2022

View full text Add to dashboard Cite

Background: Spermidine, a natural polyamine, was found critically involved in cardioprotection and lifespan extension from both animal experiments and human studies. Aims: This study aimed to evaluate the effect of serum spermidine levels on the prognosis in patients with acute myocardial infarction (AMI) and investigate the potential mediation effect of oxidative stress in the above relationship. Methods: We included 377 patients with AMI in a prospective cohort study and measured serum spermidine and oxidative stress indexes (superoxide dismutase enzymes, glutathione peroxidase, and Malondialdehyde) using high-performance liquid chromatography with fluorescence detector and enzyme-linked immunosorbent assay, respectively. The associations of spermidine with AMI outcomes were evaluated using Cox proportional hazards models. Results: 84 (22.3%) major adverse cardiac events (MACE) were documented during a mean follow-up of 12.3 ± 4.2 months. After multivariable adjustment, participants with serum spermidine levels of ≥15.38 ng/mL (T3) and 7.59–5.38 ng/mL (T2) had hazard ratio (HR) for recurrent AMI of 0.450 [95% confidence interval (CI): 0.213–0.984] and 0.441 (95% CI: 0.215–0.907) compared with the ≤7.59 ng/mL (T1), respectively. Participants in T3 and T2 had HR for MACE of 0.566 (95% CI: 0.329–0.947) and 0.516 (95% CI: 0.298–0.893) compared with T1. A faint J-shaped association was observed between serum spermidine levels and the risk of MACE (p-nonlinearity = 0.036). Comparisons of areas under receiver operator characteristics curves confirmed that a model including serum spermidine levels had greater predictive power than the one without it (0.733 versus 0.701, p = 0.041). A marginal statistically significant mediation effect of superoxide dismutase was shown on the association between spermidine and MACE (p = 0.091). Conclusions: Serum spermidine was associated with an improved prognosis in individuals with AMI, whereas the underlying mechanism mediated by oxidative stress was not found.

“…Also, as other early prognostic biochemical biomarkers of EVA, CVDs (atherosclerosis and CAD) are being actively studied: neutrophil gelatinase-associated lipocalin (NGAL) [ 14 ]; tissue inhibitor of metalloproteinase 2 (TIMP-2) [ 14 ]; fibroblast growth factor 23 (FGF-23) [ 15 , 16 ]; syndecan-1 [ 16 ]; interleukin 6 (IL-6) [ 17 ]; and galectin-3 [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Leukocyte Telomere Length as a Molecular Biomarker of Coronary Heart Disease

¹

,

²

,

³

et al. 2022

View full text Add to dashboard Cite

Background. This work is a review of preclinical and clinical studies of the role of telomeres and telomerase in the development and progression of coronary heart disease (CHD). Materials and methods. A search for full-text publications (articles, reviews, meta-analyses, Cochrane reviews, and clinical cases) in English and Russian was carried out in the databases PubMed, Oxford University Press, Scopus, Web of Science, Springer, and E-library electronic library using keywords and their combinations. The search depth is 11 years (2010–2021). Results. The review suggests that the relative leukocyte telomere length (LTL) is associated with the development of socially significant and widespread cardiovascular diseases such as CHD and essential hypertension. At the same time, the interests of researchers are mainly focused on the study of the relative LTL in CHD. Conclusions. Despite the scientific and clinical significance of the analyzed studies of the relative length of human LTL as a biological marker of cardiovascular diseases, their implementation in real clinical practice is difficult due to differences in the design and methodology of the analyzed studies, as well as differences in the samples by gender, age, race, and ethnicity. The authors believe that clinical studies of the role of the relative length of leukocyte telomeres in adult patients with coronary heart disease are the most promising and require large multicenter studies with a unified design and methodology.

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.